Novartis strikes $1.4bn deal for Tourmaline Bio

Novartis has agreed to acquire Tourmaline Bio for $1.4 billion in cash, paying $48.00 per share, representing a 59% premium to its recent closing price. This strategic acquisition bolsters Novartis's cardiovascular medicine portfolio with pacibekitug, a late-stage anti-inflammatory drug targeting IL-6, which is seen as a potential first-in-class treatment for cardiovascular risk reduction in ASCVD patients. The deal diversifies Novartis's offerings beyond traditional treatments and addresses a significant unmet medical need, with closing anticipated in Q4 2025 subject to regulatory approval.

Analysis

Novartis is executing a strategic expansion of its cardiovascular franchise through the $1.4 billion all-cash acquisition of Tourmaline Bio. The offer price of $48.00 per share represents a significant 59% premium to the prior closing price and a 127% premium to the 60-day average, signaling Novartis's high conviction in the target's lead asset, pacibekitug. This late-stage, long-acting IL-6 antibody is positioned as a potential first-in-class therapy to reduce cardiovascular risk in atherosclerotic cardiovascular disease (ASCVD) patients by targeting inflammation, a novel mechanism that diversifies Novartis's portfolio beyond traditional cholesterol and blood pressure treatments. With data from approximately 450 participants across six trials, pacibekitug adds a relatively de-risked, late-stage candidate to the pipeline. The transaction, unanimously approved by both boards, is contingent upon regulatory clearance and is anticipated to close in the fourth quarter of 2025.

Key Decisions for Investors

• For Tourmaline Bio shareholders, the $48.00 all-cash offer presents a compelling exit at a substantial premium, making it prudent to hold positions to capture this value, while monitoring for any regulatory hurdles that could jeopardize the transaction's expected Q4 2025 closing.
• Novartis investors should view this as a long-term strategic deployment of capital that strengthens its cardiovascular pipeline; the success of the deal is directly tied to the future regulatory approval and commercial performance of pacibekitug.
• Investors should consider this move a validation of targeting inflammation in cardiovascular disease, and monitor clinical and regulatory milestones for pacibekitug as they will be critical catalysts for valuing Novartis's future growth prospects in this innovative therapeutic area.